INTERVIEW: Novartis' Oncology Chief On Sharpening Its Competitive Advantage
Executive Summary
Novartis Oncology President Bruno Strigini talks about refining the pharma major's oncology strategy and its pipeline potential.
You may also be interested in...
Novartis Oncology Strategy: Focus On The Microenvironment
As ASCO approaches, Novartis tries to highlight its oncology offerings, despite a very early immuno-oncology pipeline.
Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early
Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.
Alcon Loses CEO And Eye Drugs After Dragging On Novartis Financials
Novartis is set to overhaul its eye care business Alcon after a lackluster 2015, focusing on its core Surgical and Vision Care business by cleaving its ophthalmic pharmaceuticals business and repositioning it into the Pharmaceuticals division.